Company Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives.
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
| Country | United States |
| Founded | 2020 |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Ron Bentsur |
Contact Details
Address: 1 Bridge Plaza, Suite 275 Fort Lee, New Jersey 07024 United States | |
| Phone | 201 614 3150 |
| Website | nuvectis.com |
Stock Details
| Ticker Symbol | NVCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001875558 |
| CUSIP Number | 67080T108 |
| ISIN Number | US67080T1088 |
| Employer ID | 86-2405608 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific and Business Officer |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development and Operations Officer |
| Michael Carson CPA | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |